Published in Am J Trop Med Hyg on May 01, 1991
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother (2004) 4.54
Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 4.52
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis (2014) 4.09
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg (2006) 3.08
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother (2003) 2.26
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J (2005) 2.15
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis (2008) 1.96
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J (2008) 1.91
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother (2008) 1.86
A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov (2009) 1.77
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2010) 1.70
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis (2011) 1.64
Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol (2011) 1.61
Primaquine in vivax malaria: an update and review on management issues. Malar J (2011) 1.53
Genetic diversity of Plasmodium vivax in Kolkata, India. Malar J (2006) 1.49
Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev (2008) 1.39
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc Natl Acad Sci U S A (2002) 1.39
Border malaria associated with multidrug resistance on Thailand-Myanmar and Thailand-Cambodia borders: transmission dynamic, vulnerability, and surveillance. Biomed Res Int (2013) 1.37
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J (2009) 1.33
Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar J (2011) 1.29
High genetic polymorphism of relapsing P. vivax isolates in northwest Colombia. Acta Trop (2011) 1.20
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol (2012) 1.17
Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis (2011) 1.16
Improved assessment of plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. Antimicrob Agents Chemother (2007) 1.16
Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates. Antimicrob Agents Chemother (2004) 1.12
Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother (1994) 1.10
Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar J (2011) 1.08
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China. Am J Trop Med Hyg (2011) 1.03
Malaria vaccine development. Clin Microbiol Rev (1994) 1.01
Plasmodium vivax malaria endemicity in Indonesia in 2010. PLoS One (2012) 1.01
Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar J (2009) 1.01
Genetic structures of geographically distinct Plasmodium vivax populations assessed by PCR/RFLP analysis of the merozoite surface protein 3beta gene. Acta Trop (2006) 1.00
Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. Antimicrob Agents Chemother (2014) 1.00
Seasonal prevalence of malaria in West Sumba district, Indonesia. Malar J (2009) 0.95
Application of genomics to field investigations of malaria by the international centers of excellence for malaria research. Acta Trop (2011) 0.95
The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol (1994) 0.95
Plasmodium vivax drug resistance genes; Pvmdr1 and Pvcrt-o polymorphisms in relation to chloroquine sensitivity from a malaria endemic area of Thailand. Korean J Parasitol (2015) 0.95
A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar J (2011) 0.92
Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS One (2014) 0.92
The evolution of tafenoquine--antimalarial for a new millennium? J R Soc Med (1999) 0.91
Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J (2014) 0.91
Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg (2009) 0.90
Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther (2016) 0.88
The Effect of Otostegia persica in Combination with Chloroquine on Chloroquine-Sensitive and Chloroquine-Resistant Strains of Plasmodium berghei Using In-vivo Fixed Ratios Method. Iran J Pharm Res (2012) 0.88
Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India. Malar J (2014) 0.88
Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrob Agents Chemother (2015) 0.84
Phenotyping clinical resistance to chloroquine in Plasmodium vivax in northeastern Papua, Indonesia. Int J Parasitol Drugs Drug Resist (2011) 0.84
Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev (1995) 0.84
Analysis of the dihydrofolate reductase-thymidylate synthase gene sequences in Plasmodium vivax field isolates that failed chloroquine treatment. Malar J (2010) 0.84
Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam. Antimicrob Agents Chemother (2015) 0.82
Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro. Antimicrob Agents Chemother (2012) 0.82
Plasmodium vivax msp-3α polymorphisms: analysis in the Indian subcontinent. Malar J (2016) 0.78
Plasmodium vivax mdr1 genotypes in isolates from successfully cured patients living in endemic and non-endemic Brazilian areas. Malar J (2016) 0.78
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malar J (2016) 0.75
Diagnosis and Treatment of Plasmodium vivax Malaria. Am J Trop Med Hyg (2016) 0.75
Efficacy of Chloroquine for the Treatment of Vivax malaria in Northwest Ethiopia. PLoS One (2016) 0.75
Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia. Malar J (2017) 0.75
Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria. PLoS One (2017) 0.75
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet (1994) 6.01
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 3.46
Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J Infect Dis (2002) 3.13
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 3.01
Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (1987) 2.98
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg (2003) 2.49
Diagnosis of malaria in the field by fluorescence microscopy of QBC capillary tubes. Trans R Soc Trop Med Hyg (1992) 2.39
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med (1984) 2.24
Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet (1993) 2.23
Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci (1985) 2.21
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 2.17
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Evaluating orangutan census techniques using nest decay rates: implications for population estimates. Ecol Appl (2008) 2.09
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
A shotgun optical map of the entire Plasmodium falciparum genome. Nat Genet (1999) 2.04
Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med (1989) 2.03
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Analysis of filter-paper-absorbed, finger-stick blood samples for chloroquine and its major metabolite using high-performance liquid chromatography with fluorescence detection. J Chromatogr (1983) 1.99
Status of malaria in Thailand. Southeast Asian J Trop Med Public Health (2000) 1.95
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science (1991) 1.94
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen. JAMA (1991) 1.90
Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg (1991) 1.87
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis (1995) 1.87
Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever. Am J Trop Med Hyg (1986) 1.86
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis (1995) 1.83
Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg (1998) 1.82
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol (1991) 1.78
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun (2000) 1.77
Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A (1994) 1.77
Research toward vaccines against malaria. Nat Med (1998) 1.76
Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg (1996) 1.76
In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg (1997) 1.74
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol (1991) 1.73
Tropical medicine. BMJ (2000) 1.67
Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J Infect Dis (1998) 1.65
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A (2001) 1.63
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol (1992) 1.62
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol (1995) 1.60
Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci U S A (2001) 1.59
Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. Am J Trop Med Hyg (2000) 1.58
Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates. J Cell Biol (1992) 1.58
Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg (2001) 1.57
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Rare quadruple malaria infection in Irian Jaya Indonesia. J Parasitol (1999) 1.52
Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med (1986) 1.51
Epidemic dengue transmission in southern Sumatra, Indonesia. Trans R Soc Trop Med Hyg (2001) 1.51
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. J Clin Microbiol (1992) 1.50
Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis (1999) 1.49
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med (1982) 1.47
Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med (1991) 1.46
Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science (1985) 1.44
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science (1991) 1.43
Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol Biochem Parasitol (2001) 1.40
A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull World Health Organ (1990) 1.40
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis (2001) 1.40
Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. J Infect Dis (1984) 1.38
Review on global co-transmission of human Plasmodium species and Wuchereria bancrofti by Anopheles mosquitoes. Infect Genet Evol (2009) 1.38
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett (1990) 1.36
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine (2000) 1.34
Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol (1996) 1.34
Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Mol Biochem Parasitol (1992) 1.34
Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect Immun (1994) 1.32
Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol (2000) 1.32
Use of a DNA probe to detect Salmonella typhi in the blood of patients with typhoid fever. J Clin Microbiol (1989) 1.29
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis (1993) 1.28
Comparison of immunity to malaria in Sudan and Indonesia: crisis-form versus merozoite-invasion inhibition. Proc Natl Acad Sci U S A (1984) 1.28
Performance of the OptiMAL assay for detection and identification of malaria infections in asymptomatic residents of Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.26
Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J Trop Med Hyg (1993) 1.26
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet (1995) 1.25